From: Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy
n = 95
Median
Age
77 (48-91) years
Sex
Male
49 (51.6%)
Female
46 (48.4%)
Operable
14 (14.7%)
Inoperable
81 (85.3%)
KPS
80-100
63 (66.3%)
<70
32 (32.7%)
Clinical follow-up
16.33 (1.13-64.2) months